Pharma & Biotech Global Week in Review 2 Sept 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

Glivec (Imatinib) – India: Novartis persists in challenge to Indian patent law; Justice Katju recuses himself (Spicy IP) (Intellectual Property Watch)

Ultracet (Tramadol/Acetaminophen) – US: CAFC vacates Ultracet obviousness decision: Ortho-McNeil Pharmaceutical, Inc v Teva Pharmaceuticals (not precedential) (Patently-O) (Patent Docs) (SmartBrief)

 
General

The tragedy of a bad idea – concept of the ‘tragedy of the anticommons’ (Patent Docs)

BioWorld reports on the top 25 biotech drugs (Patent Docs)

Branded generics; did The Economist get it right? (IP finance)

Access to research – the seeds of thought, the wisdom of tradition (Patenting Lives)

Brazil/US: US dodges Brazil’s WTO pharma patent bullet (IAM)

EU: Synthon v Merz Pharma: SPC questions for the ECJ (The SPC Blog)

India: A ‘spurious’ definition: Need to amend the Drug and Cosmetic Act (Spicy IP)

India may be nearing dispute settlement with EU over generic drug seizures (Intellectual Property Watch)

UK: Parallel imports lead to UK drug shortages (IPKat)

US: ACLU moves for summary judgment in case challenging patentability of BRCA1 and BRCA2 breast cancer genes (Holman’s Biotech IP Blog) (Patently-O)

US: BPAI construes ‘pharmaceutical compound’ as a compound that ‘achieve[s] any discernable physiological effect’: Ex parte Pickar (Gray on Claims)

US: TET Systems and Pharmaccet settle patent litigation over gene expression technology (IP Frontline)

US: Paragraph IV certification reported by USFDA (June-August 2009) (Generic Pharmaceuticals and Patentology)

US: Deloitte white paper addresses unintended consequences of follow-on biologic regulatory pathway (Patent Docs)

US: Should exclusivity periods be tailored to technology? (IP Osgoode)

US: PTO issues interim examination instructions for patentable subject matter and invites comments (Patents4Life) (Patents4Life)

US: Biotech/Pharma financing improving, R&D spending up (Patent Docs)

 
Products

Cymbalta (Duloxetine) – US: Eli Lilly files patent infringement suit against Anchen following Para IV challenge (Patent Docs)

Glivec (Imatinib) – India: Novartis persists in challenge to Indian patent law; Justice Katju recuses himself (Spicy IP) (Intellectual Property Watch)

Prezista (Darunavir) – India: MSF announces Patent Office rejected patents on AIDS drugs Tenofovir and Darunavir (Intellectual Property Watch)

Tarceva (Erlotinib) – India: Supreme Court dismisses Roche ‘Tarceva’ petition (Spicy IP)

Taxotere (Docetaxel) – US: Aventis files patent infringement suits against Sun Pharmaceutical in response to Para IV challenge (Patent Docs)

Thalomid (Thalidomide) – Should patient suggestion for treatment be compensated?: Jacobson v Celgene (Patent Baristas)

Ultracet (Tramadol/Acetaminophen) – US: CAFC vacates Ultracet obviousness decision: Ortho-McNeil Pharmaceutical, Inc v Teva Pharmaceuticals (not precedential) (Patently-O) (Patent Docs) (SmartBrief)

Viread (Tenofovir) – India: MSF announces Patent Office rejected patents on AIDS drugs Tenofovir and Darunavir (Intellectual Property Watch)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: